共 50 条
- [21] Phase II trial of sequential dose-dense epirubicin/cyclophosphamide (E/C) followed by docetaxel/capecitabine (D/X) as adjuvant or neoadjuvant chemotherapy for patients with HER2-negative breast cancer (BC)JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)De la Cruz, S.Aramendia, J. M.Espinos, J.Fernandez-Hidalgo, O.Santisteban, M.Arbea, L.Aristu, J.Garran, C.Martinez-Monge, R.Martinez-Regueira, F.Nieto, Y.
- [22] A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity AnalysisINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S48 - S49Shenouda, G.Souhami, L.Petrecca, K.Owen, S.Panet-Raymond, V.Carvalho, T.Guiot, M. C.Abdulkarim, B. S.
- [23] GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analysesCANCER RESEARCH, 2016, 76Moebus, V.Lueck, H-JForstbauer, H.Wachsmann, G.Ober, A.Schneeweiss, A.Christensen, B.von Abel, E.Grischke, E-MHoeffkes, H-GKlare, P.Yon-Dschun, K.Schmatloch, S.Furlanetto, J.Burchardi, N.Von Minckwitz, G.Loibl, S.
- [24] Results of a Phase 2 Clinical Trial of Neo-Adjuvant Temozolomide (TMZ), Followed by Concurrent TMZ and Hypofractionated Accelerated External Beam Radiation Therapy (Ac-EBRT) With Limited Margins, and Adjuvant TMZ for Patients With Glioblastoma Multiforme (GBM)INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S160 - S160Shenouda, G.Souhami, L.Panet-Raymond, V.Abdulkarim, B.Cury, F.Owen, S.Kavan, P.Petrecca, K.Guiot, M.
- [25] Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER TrialCANCER, 2020, 126 (06) : 1175 - 1182Papakonstantinou, AntroulaMatikas, AlexiosBengtsson, Nils OlofMalmstrom, PerHedayati, ElhamSteger, GuentherUntch, MichaelHubbert, LailaJohansson, HemmingHellstrom, MatsGnant, MichaelLoibl, SibylleGreil, RichardMoebus, VolkerFoukakis, TheodorosBergh, Jonas
- [26] EFFICACY AND SAFETY OF METFORMIN PLUS LOW-DOSE TEMOZOLOMIDE IN PATIENTS WITH RECURRENT OR REFRACTORY GLIOBLASTOMA: A RANDOMIZED, PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, CONTROLLED, PHASE 2 TRIALNEURO-ONCOLOGY, 2023, 25Yoon, Wan SooChang, Jong HeeKim, Jeong HoonKim, Yu JungJung, Tae YoungYoo, HeonKim, Se-HyukDo-Hyun NamKim, Tae MinKim, Se HoonPark, Sung HyeLee, Youn SooKim, Hyeon WooHong, Yong-KilYang, Seung Ho
- [27] APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIESNEURO-ONCOLOGY, 2023, 25Rahman, RifaquatTrippa, LorenzoFell, GeoffreyLee, EudociaArrillaga-Romany, IsabelTouat, MehdiDrappatz, JanWelch, MaryGalanis, EvanthiaAhluwalia, ManmeetColman, HowardNabors, BurtHepel, JaroslawElinzano, HeinrichSchiff, DavidChukwueke, UgonmaBeroukhim, RameenNayak, LakshmiMcFaline-Figueroa, Jose RicardoBatchelor, TracyRinne, MikaelKaley, ThomasLu-Emerson, ChristineMellinghoff, IngoBi, Wenya LindaArnaout, OmarPeruzzi, Pier PaoloHaas-Kogan, DaphneTanguturi, ShyamCagney, DanielAizer, AyalDoherty, LisaSantagata, SandroMeredith, DavidChiocca, E. AntonioReardon, DavidAlexander, BrianLigon, KeithWen, Patrick
- [28] A Phase 2 Trial of Hypofractionated-Intensity Modulated Radiation Therapy (Hypo-IMRT) Combined With Temozolomide (TMZ) and Bevacizumab (BEV) for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S284 - S285Carlson, J. A.Ney, D.Reddy, K.Gaspar, L. E.Kavanagh, B. D.Damek, D.Lillehei, K. O.Chen, C.
- [29] BEVACIZUMAB (BV) IN COMBINATION TO TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A PHASE 2 TRIALNEURO-ONCOLOGY, 2009, 11 (05) : 634 - 634Desjardins, AnnickReardon, David A.Peters, Katherine B.Herndon, JamesKirkpatrick, JohnGururangan, SridharanSampson, John H.Friedman, Allan H.Friedman, HenryVredenburgh, James J.
- [30] The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patientsBMC CANCER, 2018, 18Petrera, MarilenaPaleari, LauraClavarezza, MatteoPuntoni, MatteoCaviglia, SilviaBriata, Irene MariaOppezzi, MassimoMislej, Eva MihajlovicStabuc, BorutGnant, MichaelBachleitner-Hofmann, ThomasRoth, WilfriedScherer, DominiqueHaefeli, Walter-E.Ulrich, Cornelia M.DeCensi, Andrea